MedPath

COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff

Completed
Conditions
COVID
Interventions
Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2
Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2
Registration Number
NCT04346186
Lead Sponsor
Herlev Hospital
Brief Summary

During the COVID-19 pandemic several countries have seen a high risk of transmission for health care personnel, with some countries having as many 20-25% of nurses and doctors either infected or showing symptoms of COVID-19.

In this prospective cohort study, we will systematically screen all hospital staff in the Capital Region of Denmark for IgM and IgG antibodies against SARS-CoV-2 using a point of care tests and an Elisa kit.

Testing will be offered 3 times: In April 2020, Maj 2020 and September 2020. All participants will submit a questionnaire regarding exposures, risk factors and symptoms of COVID-19 in relation to each testing. Follow-up will be through electronic patient records and national registries.

We will compare the group of health care personnel with data from a control group of healthy volunteer blood donors from the Danish Blood Donor Study.

The aim of the study is to investigate the proportion of hospital staff with SARS-CoV-2 antibodies during the study period compared to a control group representing the Danish population. We will compare the test characteristics of the two methods of testing, a point of care test and Elisa.

Further, we will investigate the extent to which prior immunization or infection is protective for future infection with COVID-19.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
44698
Inclusion Criteria
  • >18 years old
  • Consent to participation
  • Employed at a Hospital in the Capitial Region of Denmark
Exclusion Criteria
  • None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Hospital Staff in the Capital Region of DenmarkIgM and IgG diagnostic kits to SARS-CoV-2-
Healthy volunteer blood donorsIgM and IgG diagnostic kits to SARS-CoV-2-
Healthy volunteer blood donorsElisa-test for IgM and IgG to SARS-CoV-2-
Hospital Staff in the Capital Region of DenmarkElisa-test for IgM and IgG to SARS-CoV-2-
Primary Outcome Measures
NameTimeMethod
Comparison of the point of care test and Elisa5 months

Comparison of the resultat from the point of care test and with results from Elisa

Re-infection rate360 days

Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19

Positive IgM/IgG tests5 month

Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population

IgM/IgG positive participants on follow-up test5 months

Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (14)

Psykiatrisk Center Sankt Hans

🇩🇰

Roskilde, Denmark

Psykiatrisk Center Amager

🇩🇰

Copenhagen, Denmark

Rigshospitalet

🇩🇰

Copenhagen, Denmark

Bornholms Hospital

🇩🇰

Rønne, Denmark

Psykiatrisk Center Bornholm

🇩🇰

Rønne, Denmark

Psykiatrisk Center Ballerup

🇩🇰

Ballerup, Denmark

Psykiatrisk Center Stolpegaard

🇩🇰

Gentofte, Denmark

Herlev Hospital

🇩🇰

Herlev, Region Hovedstaden, Denmark

Bispebjerg Hospital

🇩🇰

København NV, Region Hovedstaden, Denmark

Psykiatrisk Center København

🇩🇰

Copenhagen, Denmark

Børne- og Ungdomspsykiatrisk Center

🇩🇰

Glostrup, Denmark

Psykiatrisk Center Glostrup

🇩🇰

Glostrup, Denmark

Nordsjaellands Hospital

🇩🇰

Hillerød, Denmark

Psykiatrisk Center Nordsjælland

🇩🇰

Hillerød, Denmark

© Copyright 2025. All Rights Reserved by MedPath